Literature DB >> 24332038

The evolution of tumor classification: a role for genomics?

Paul A Bunn1, Wilbur Franklin2, Robert C Doebele3.   

Abstract

Lung cancers are divided into four types according to their histologic appearance. Therapeutic decisions are partly based on histology. A recent study indicates that certain molecular alterations associate with histology and that therapies directed to these molecular changes improve outcome, indicating that genomic information should be incorporated into future tumor classification.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 24332038      PMCID： PMC3928679          DOI： 10.1016/j.ccr.2013.11.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

Authors:  William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

Review 2.  Recent clinical advances in lung cancer management.

Authors:  David H Johnson; Joan H Schiller; Paul A Bunn
Journal:  J Clin Oncol       Date:  2014-02-24       Impact factor: 44.544

Review 3.  ALKoma: a cancer subtype with a shared target.

Authors:  Hiroyuki Mano
Journal:  Cancer Discov       Date:  2012-05-21       Impact factor: 39.397

Review 4.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

5.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

6.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

7.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

8.  A genomics-based classification of human lung tumors.

Authors: 
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956
  8 in total
  3 in total

1.  Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging.

Authors:  Yi-Hsuan Chi; Jong-Kai Hsiao; Ming-Huang Lin; Chen Chang; Chun-Hsin Lan; Han-Chung Wu
Journal:  Theranostics       Date:  2017-04-10       Impact factor: 11.556

2.  Single nucleotide polymorphism rs11614913 associated with CC genotype in miR-196a2 is overrepresented in laryngeal squamous cell carcinoma, but not salivary gland tumors in Polish population.

Authors:  Marcin Skalski; Adam Ustaszewski; Katarzyna Jaskiewicz; Katarzyna Kiwerska; Malgorzata Wierzbicka; Hanna Klimza; Reidar Grenman; Maciej Giefing
Journal:  J Appl Genet       Date:  2018-04-29       Impact factor: 3.240

3.  Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.

Authors:  Zhaoyang Sun; Yu Zeng; Ting Yuan; Xiaoying Chen; Hua Wang; Xiaowei Ma
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.